Simcere Zaiming Pharmaceutical Co Ltd is part of Simcere Pharmaceutical Group

Simcere Zaiming Pharmaceutical Co Ltd is part of Simcere Pharmaceutical Group

Neuron23 Inc, owned by Origenis GmbH operates as a biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. The company leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases, providing patients with the right medicines suffering from genetic disorders.In March 2022, Neuron23 Inc closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing to $213.5 million.In December 2020, the company announced that it had closed USD 113.5 million Series A (USD 33.5 million) and B (USD 80 million) financing. The Series A was led by Westlake Village BioPartners, and Kleiner Perkins, and Series B was led by Redmile Group. Other Series B investors include Westlake Village BioPartners, Kleiner Perkins, Cowen Healthcare Investments, Acorn